Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 7 Other hematologic neoplasm 6 Myeloid 5 Thoracic 4 Sarcoma 2 Genitourinary 2 Tumor-Agnostic 1 Head & Neck 1 Gastrointestinal 1 Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 631 Radiotherapy 339 pembrolizumab 329 Cetuximab 284 Docetaxel 226 Radiotherapy, Intensity-Modulated 221 Fluorouracil 199 Carboplatin 198 Paclitaxel 161 Nivolumab 145 Gemcitabine 125 Magnetic Resonance Spectroscopy 99 Radiation 91 Drug Therapy 86 Capecitabine 77 toripalimab 75 Surveys and Questionnaires 73 Surgical Procedures, Operative 72 Biopsy 62 durvalumab 61 Chemoradiotherapy 52 Blood Specimen Collection 52 Cyclophosphamide 50 Specimen Handling 47 camrelizumab 46 Radiosurgery 46 Erlotinib Hydrochloride 46 Standard of Care 44 130-nm albumin-bound paclitaxel 44 tislelizumab 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

mocetinostat × Head & Neck × Clear all

NCT02993991 2017-12-29

PRIMED-001

University Health Network, Toronto

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon ⚡